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Abstract:  The  factor  VIII  gene  (F8)  intron  22  inversion  (Inv22)  is  a  paradigmatic 
duplicon-mediated  rearrangement,  found  in  about  one  half  of  patients  with  severe 
hemophilia  A  worldwide.  The  identification  of  this  prevalent  cause  of  hemophilia  was 
delayed for nine years after the F8 characterization in 1984. The aim of this review is to 
present the wide diversity of practical approaches that have been developed for genotyping 
the Inv22 (and related int22h rearrangements) since discovery in 1993. The sequence—
Southern blot, long distance-PCR and inverse shifting-PCR—for Inv22 genotyping is an 
interesting example of scientific ingenuity and evolution in order to resolve challenging 
molecular diagnostic problems.  
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1. Introduction  
Scientific development is not smoothly continuous but rather occurs in steps. There are several 
examples that prove the causative connection between each one of these steps and the use of novel 
experimental approaches. A typical example in the area of life sciences is the method of polymerase 
chain reaction (PCR) [1], which has revolutionized molecular diagnosis in medicine. Therefore, to tell 
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the story of technical developments in a scientific discipline is perhaps the best way to understand it in 
depth. Notably, due to the molecular characteristics of the genes involved in hemophilia A and B (i.e., 
their  different  molecular  sizes  and  structure  complexities)  a  significant  number  of  scientists  who 
designed  and  developed  innovative  technical  approaches  for  mutation  detection  and  genotyping, 
worked in hemophilia. 
Hemophilia A (HA) (OMIM 306700) is the most severe inherited bleeding disorder that affects 
humans. A deficiency in FVIII clotting activity leads to this coagulopathy, which affects 1 in 5,000 
males worldwide. This makes HA one of the most common X-linked inherited diseases. Virtually all 
patients with HA associate with deleterious mutations within the coagulation factor VIII gene (F8). A 
familial history of the disease is known in about two thirds of cases, and it appears sporadically in one 
third of cases. HA is expressed in a wide range of clinical severities and these differences associate 
with the type and location of the causative gene defect. Therefore, HA is caused by a heterogeneous 
spectrum of molecular defects in F8 including deletions, large DNA inversions, nonsense mutations, 
ins/del-frameshifts, splice variants and a large number of missense point mutations, all of which can 
cause defects in the expression, secretion, and/or half-life of FVIII in circulation.  
HA can be classified by the residual clotting activity of FVIII as severe, moderate or mild disease, 
affecting about 40%, 10% and 50% of patients with HA, respectively. As a recessive X-linked disorder, 
the residual activity of plasmatic FVIII in heterozygous carrier females of severe F8 mutations is usually 
~50% with respect to a non-carrier individual. Although extremely rare, homozygous females may also 
suffer from hemophilia in a similar way to hemizygous male patients [2]. However, most of the few 
cases of hemophilia expression in females are due to the coexistence of skewed Lyonization (biased X-
chromosome inactivation) and the heterozygous carrier condition [3].  
An international database, the HA mutation, structure, test and resource site (HAMSTeRS, URL: 
http://hadb.org.uk)  contains  extensive  information,  including  a  curated  list  of  previously  reported 
mutations and polymorphisms in F8 [4]. Today, 1,209 total unique mutations of different types are 
collected in the worldwide database HAMSTeRS, and 797 are single-base substitutions (point mutations) 
(database  accessed  17/10/2011).  Approximately  one  half  of  the  severe  cases  of  HA  are  caused  by 
inversions  between  a  sequence  located  within  intron  22  of  the  F8  gene  and  sequences  outside  the 
F8 gene.  
Also characteristic of HA is the development of inhibitory antibodies against therapeutic FVIII 
(inhibitors)  in  approximately  15–35%  of  patients  with  severe  HA.  Particularly,  FVIII  inhibitors 
neutralize the substituted FVIII in about 21% of intron 22 inversions (a large series of patients with 
severe HA from the Bonn Centre, Germany) [5], a rate slightly higher than the average across all 
severe  HA  causative  mutations,  but  lower  than  those  cases  associated  with  large  deletions  or  
nonsense mutations. 
2. Milestones in Hemophilia A Mutation Characterization  
2.1. 1984–1993: Cloning and Characterization of the Human Coagulation Factor VIII 
The human F8 gene was cloned between 1982 and 1984 [6]. At that time the gene was the largest 
described [6], and at approximately 187 kb, remains one of the largest (chrX:154,064,070-154,250,998, 
UCSC genome browser, access date 17/10/2011 [7]). Genetic mapping positioned the F8 gene in the Int. J. Mol. Sci. 2011, 12  7273 
 
 
most distal band (Xq28) of the long arm of the X-chromosome. The F8 gene contains 26 exons, which 
vary in length from 69 to 3,106 base pairs (bp). Intron sequences correspond to 177.9 kb, and are 
removed  from  the  primary  transcript  product  during  splicing  to  generate  a  mature  F8  mRNA  of 
approximately 9 kb in length that predicts a precursor protein of 2,351 amino acids. Of the larger 
intron sequences, we found six that are greater than 14 kb (introns 1, 6, 13, 14, 22 and 25), with intron 
22 the largest at 32.8 kb in length [6].  
Levinson et al. (1990) [8] found a curious example of a gene within a gene. Looking for transcripts 
within a region of Xq28 associated with several neurological disorders, the authors identified a CpG 
island in the largest F8 intron. This CpG island was associated with a 1.8 kb transcript referred to as 
the A gene (F8A). The nested F8A gene was oriented in opposite direction to that of F8 and contained 
no intervening sequences. Computer analysis of the sequence suggested that the F8A gene encodes a 
protein with the complication that codon usage analysis suggested a frameshift halfway through the 
gene. Freije and Schlessinger (1992) [9] subsequently demonstrated that the X-chromosome contains 
three copies of F8A and its adjacent regions, one in intron 22 and two telomeric and approximately  
500 kb upstream to the F8 gene transcription start site.  
In 1992, Levinson et al. reported another transcript of 2.5 kb, F8B, that emanates from the same F8 
intron 22 CpG island as F8A and transcribes in the same direction as F8. The divergent transcripts  
F8A and F8B originate from within 122 bases of each start point. The newly identified 5' exon of F8B 
in F8 intron 22 potentially codes for eight amino acids and was spliced to F8 exons 23-26, with the F8 
reading frame maintained [10]. 
Following these discoveries, Lakich et al. (1993) [11] pointed out that intron 22 was unusual in 
many respects. Containing 32.8 kb, it is the largest intron in the F8 gene. It also contains a CpG island, 
located about 10 kb downstream of exon 22 [11]. This CpG island appears to serve as a bidirectional 
promoter for the F8A and F8B genes, which are both expressed ubiquitously in different tissues [10]. 
In 2001, F8A gene was shown to code for a 40 kD huntingtin-associated protein, termed HAP40 [12] 
and  is  thought  to  be  involved  in  the  aberrant  nuclear  localization  of  the  huntingtin  protein  in 
Huntington disease. The function of F8B is not known. Because there is no F8B equivalent in the 
mouse  genome,  transgenic  mice  that  express  the  wild-type  human  F8B  under  the  control  of  a 
cytomegalovirus  promoter  have  been  used  to  understand  its  function.  Surprisingly,  these  F8B 
transgenic mice showed growth retardation, microcephaly and severe ocular defects, evidence that 
should encourage further studies of this protein [13].  
2.2. 1993–2005: F8 Intron 22 Inversion Discovery and Detection 
In 1993, two research groups—one led by Jane Gitschier in USA and the other one by Francesco 
Giannelli  in  UK—independently  observed  that  one  half  of  severe  HA  patients  had  no  detectable 
mutation in the promoter, coding sequences or normal RNA processing signals of the F8 gene [11,14]. 
Instead they revealed a unique mRNA defect that prevents the amplification of the message across the 
boundary between exon 22 and 23. This feature located the defect to internal regions of intron 22 and a 
model was proposed based on recombination between homologous F8A sequences located in intron 22 
and upstream of the F8 gene. Such event of homologous recombination would lead to an inversion of all 
intervening DNA and a disruption of the F8 gene. Both groups presented evidence to support this model.  Int. J. Mol. Sci. 2011, 12  7274 
 
 
Figure 1. Schematic view of the F8 int22h normal gene regions (A, B) and int22h-related 
recombination variants (C-G). From top down, the last Mb of Xq28 is shown representing: 
(A) the normal F8 wild-type variant h123 (according to Xq->Xtel orientation of int22h-1,  
h-2 and h-3 sequences); (B) the normal F8 wild-type variant h132 (non-deleterious inversion 
polymorphism h123/h132); (C) HA-associated Inv22 type I originating from recombination 
between h1 and h3 on normal variant h123 shown in (A); (D) HA-associated Inv22 type II 
originating from recombination between h1 and h2 on normal variant h132 shown in (B);  
(E) HA-associated Del22 type I originating from recombination between equally oriented 
int22h-1 and h-3 on variant h132 (B); (F) HA-associated Del22 type II originating from 
recombination  between  int22h-1  and  h-2  on  variant  h123  (A),  (Del22  notation: 
NC_000023.10:  g.154,118,607_154,615,713del);  and  (G)  Example  of  non-HA-associated 
Dup22 originating from recombination between equally oriented int22h-1 and h-2 on variant 
h123 (A), (Dup22 notation: NC_000023.10: g.154,118,607_154,615,713dup).  
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Unbroken  F8  gene  sequences  are  shown  as  green  hatched  boxes  and  rearranged  F8 
sequences  as  orange  hatched  boxes;  intragenic  int22h-1  is  shown  as  a closed  chevron; 
int22h-2 and int22h-3, within the arms of a large imperfect palindrome (blue), are shown as 
grey and open chevrons, respectively. Chimeric int22h sequences are denoted as [/] e.g., 
int22h-1/-2 represents the chimera between h-1 and h-2. Each schematic displays: (a) IS-
PCR based approaches developed by Rossetti et al. [15,16], wherein “B” represents a Bcl I 
restriction site after self-end ligation; (b) Southern blot analysis as described by Lakich et al. 
(1993) [11], wherein dashed lines show Bcl I restriction fragment sizes (kb); and (c) LD-
PCR based approaches of Bagnall et al. (2006) [17] (upper) and Liu et al. (1998) [18] 
(lower). Please refer to text for further explanation of details, including derivation of primers 
with orientation marked by arrowheads. 
Lakich et al. (1993) further described a Southern blot assay based on Bcl I restriction and an F8A 
probe for which the sizes of two of the three normal hybridization bands were characteristically altered 
in patients presenting intron 22 inversions (Inv22) [11] [Figure 1A-D(b)]. They suggested that this 
assay should permit genetic prediction of HA in approximately 45% of families with severe disease [11]. 
Both the USA and UK groups found that this mutation occurred at the surprising rate of approximately 
4 × 10
−6 per gene, per gamete, per generation [11,14]. 
2.2.1. First Generation: Southern Blot Analysis as the Gold Standard and Early Findings about Inv22  
Southern blot analysis, as described by Lakich et al. (1993) [11], is still considered the reference 
method for Inv22 genotyping. These investigators showed that Inv22 can present two different band 
patterns named distal or type I, and proximal or type II (Inv22-1 and Inv22-2, respectively). Inv22 
Southern blot analysis is defined by Bcl I enzyme restriction and a labeled probe (900 bp Eco RI-Sac I 
fragment of plasmid p462.6, ATCC #57203) corresponding to the F8A gene located within F8 intron 
22 and therefore also the two extragenic copies. Accordingly, Southern blot analysis resolves different 
patterns each containing three signals per allele, i.e., no-Inv22 (normal allele) associated with signals 
of 21.5, 16, and 14 kb [Figure 1A(b) and 1B(b)]; Inv22-1, with signals of 20.0, 17.5 and 14.0 kb 
[Figure 1C(b)]; and Inv22-2, with signals of 20.0, 16.0, and 15.5 kb [Figure 1D(b)]. 
Southern blot analysis is technically robust, enables identification of all types of inversions (Inv22-1 
and  Inv22-2),  and  permits  a  semiquantitative  evaluation  of  Inv22  heterozygous  carrier  mosaicism  
as in the case described by Oldenburg et al. (2000) [19]. However, this technique is labor-intensive 
requiring 8–10 days to obtain the results. Use of hazardous radiochemicals is a further disadvantage 
and requires authorized personnel, although use of chemiluminescence probe labeling may circumvent 
these potential risks.  
Interestingly, Rossiter et al. (1994) [20] found that Inv22 originates predominantly from male germ 
cells and hypothesized that the presence of a second X chromosome in female meiosis would hinder 
the  intrachromosomal  non-allelic  pairing  required  for  Inv22.  They  presented  convincing  evidence 
supporting their findings using linkage analysis. This approach confirmed that, when occurring at the 
grandparents’ generation, the Inv22 was always associated with the grandfather germline (20 out of 20 
informative families studied), whereas only one out of 50 mothers of sporadic cases with severe HA 
and the Inv22 were carriers. Contemporaneously, Tizzano et al. (1995) [21] observed in a Spanish Int. J. Mol. Sci. 2011, 12  7276 
 
 
population that all mothers of patients with isolated HA caused by the Inv22 resulted from carriers, 
also indicating that Inv22 originates in male germ cells.  
Oldenburg et al. (2000) [19] reported the first instance of Inv22 presenting as somatic mosaicism in 
a  female,  affecting  only  about  50%  of  lymphocyte  and  fibroblast  cells.  Supposing  a  postzygotic 
de novo mutation as the usual cause of somatic mosaicism, the finding implies that the Inv22 mutation 
is not restricted to meiotic cell divisions but can also occur during mitotic cell divisions, either in germ 
cell precursors or in somatic cells. 
Aiming to define the exact extent of the homologous sequences involved in the Inv22 crossing over 
event, Naylor et al. (1995) [22] studied an intragenic clone containing F8 intron 22, which contains a 
copy of F8A, and two extragenic clones each with a single copy of F8A located by the Xq telomere 
using  PCR  amplification,  chemical  cleavage  of  mismatch  (CCM)  and  DNA  sequencing.  They 
precisely defined the repeated region of 9.5 kb and named it int22h-1 (intron 22 homologous region-1) 
(intragenic to F8), and int22h-2 and int22h-3 (both extragenic to F8). The inversion junctions were 
shown to represent precise exchanges between the int22h repeats without insertions or deletions, thus 
providing conclusive evidence for homologous recombination [22]. The three copies of int22h were 
compared  along  more  than  8  kb  of  their  length,  using  CCM  analysis,  and  found  to  be  99.9%  
similar [22]. The presence of such long and almost identical inverted repeats near the Xq telomere 
could account for the high frequency at which the inversions occur [22]. 
Antonarakis et al. (1995) [23] collected data on 2,093 samples from laboratories all over the world 
and concluded that the common inversion mutations are found in 42% of patients with severe HA 
(35% of Inv22 type I, 7% of type II and 0.05% of rare variants such as types IIIa and IIIb). Whereas 
98% of all mothers of patients with Inv22 were carriers, data from this study was only one de novo 
inversion event occurring in maternal somatic cells for every 25 mothers of sporadic cases. When the 
maternal  grandparental  origin  of  inversions  was  examined  the  ratio  of  de  novo  occurrences  in 
male:female germ cells was 69:1. In Argentina, De Brasi et al. (2000) [24] found similar figures for 
Inv22 type I and type II, although they did not find rare types in a group of 34 patients with severe HA 
(i.e., 41% of total Inv22, 35% of Inv22-1 and 6% of Inv22-2). According to previous series and the 
evidence discussed above, the Argentine series showed that all mothers of patients with the Inv22 (and 
particularly those mothers of isolated cases of hemophilia) were conventional heterozygous carriers, as 
detected in peripheral blood DNA samples, excluding the possibility of de novo mutation in their gonads. 
2.2.2. Second Generation: Long Distance-PCR Based Approaches 
During the early 1990s, the Inv22 was detectable only by labor-intensive Southern blot analysis. 
Therefore, a simpler, more rapid and less expensive test for Inv22 genotyping was highly desirable. 
Steve Sommer in USA designed a single-tube PCR assay that combines overlapping PCR [25] with 
long distance-PCR (LD-PCR) [26] to achieve the genetic diagnosis of Inv22 causing severe HA [18]. 
The new method was simple, rapid and relatively inexpensive and thus became the method of choice in 
many laboratories worldwide.  
The inversion was detected by performing LD-PCR directly from genomic DNA with four primers 
that differentiate the wild-type, Inv22, and carrier genotypes. Two primers, P and Q, located within the 
F8 at positions −1,212 bp and +1,334 bp flanking int22h-1, when combined with two different primers, Int. J. Mol. Sci. 2011, 12  7277 
 
 
A and B, flanking the two extragenic repeats int22h-2 and int22h-3 each at −167 bp and +118 bp, yield 
segments PQ (12 kb) and AB (10 kb) in a hemizygous individual without Inv22 and segments PB  
(11 kb) and AQ (11 kb) along with the 10 kb AB segment from the intact extragenic homolog in a 
patient with the Inv22 [Figure 1A-D(c)]. This assay does not differentiate Inv22 types I and II. Inv22 
female carriers produce PQ, PB, AQ, and AB segments. In all cases, an AB segment serves as an 
internal  control  because  at  least  one  copy  of  int22h-2  or  int22h-3  remains  intact.  The  three  long 
amplimers were separated by agarose gel electrophoresis 0.6% for 6–8 hours [18].  
Efficient amplification of the four segments depended on three unusual modifications for LD-PCR 
protocols: (i) high concentrations of dimethyl-sulfoxide; (ii) addition of 7-deaza-dGTP; and (iii) high 
concentration of a mix of Taq and Pwo DNA polymerases [18]. However, one of the segments was 
amplified much more efficiently than the others under standard three-temperature cycling conditions. 
Consequently, to facilitate the uniform  amplification of the multiple regions, subcycling-PCR was 
included in this protocol [27].  
The  accomplishment  to  amplify  long  amplimers  encompassing  int22h  duplicons  by  Sommer’s 
group opened the possibility to investigate a highly informative restriction fragment length polymorphism 
(RFLP) of enzyme Xba I [28]. Notably, the contemporary reports of El-Maari et al. (1999) [29] and 
De Brasi  et  al.  [30]  both  described  methods  based  on  hemispecific  LD-PCR  for  Xba  I  RFLP 
genotyping, one primer targeting single copy DNA on F8 intron 22 and the second primer targeting 
int22h repeat sequence. By application of the same approach of hemispecific LD-PCR for int22h-1 
specific amplification followed by nested PCR amplification, Bowen et al. (2000) [31] presented a 
new RFLP of the restriction enzyme Msp I that proved heterozygous in about 46% of females of 
Caucasian origin. In addition, De Brasi et al. (2003) [32] reported streamlined genotyping of the Xba I 
and Msp I RFLP by use of a separate LD-PCR product obtained with primers P and Q [18] to specifically 
amplify int22h-1 followed by nested PCR. The authors reported a combined heterozygosity of 63% in 
Argentine population, which is an exceptionally high figure for such linked markers (750 bp).  
Contrasting with the significant virtues of LD-PCR for Inv22 genotyping, amplification of such 
long amplimers (>10 kb) including a tract of about 3.3 kb with 79% of CG content made this assay 
somewhat dependent on narrow ranges of input DNA qualities, thermocycling and reagent conditions [27]. 
With an objective to improve Inv22 genotyping efficiency, Bowen and Kenney (2003) [33] unleashed 
the multiplex LD-PCR single tube reaction [18] into four separate LD-PCR reactions for each of the 
primer pairs PQ, PB, AQ and AB [Figure 1A-D(c)]. This separation permitted more robust amplification 
for each primer pair, and results were readily interpretable using standard agarose gel electrophoresis.  
2.2.3. Third Generation: Inverse Shifting-PCR Based Approaches 
In  order  to  overcome  the  problems  associated  with  direct  amplification  of  int22h  duplicons,  
Rossetti et al. (2005) [15] designed an alternative approach for Inv22 genotyping based on a variant of 
the classical inverse-PCR designed by Ochman et al. (1988) [34]. Novel Inv22 inverse-PCR analysis 
was inspired by the typical signal shift from 21.5 to 20 kb on Southern blot autoradiograms indicative 
of the presence of Inv22 type I or type II [14]. This alternative inverse-PCR based protocol included 
three steps: (i) Bcl I restriction; (ii) self-ligation of restriction fragment ends yielding Bcl I circles; and 
(iii) standard multiplex PCR analysis (Figure 2). Three years later, this approach was named inverse Int. J. Mol. Sci. 2011, 12  7278 
 
 
shifting-PCR (IS-PCR) [16] because it differs from classical inverse-PCR in that primers target at short 
definite distances from the site of restriction/ligation and, therefore, a sequence change associated with 
a particular rearrangement generates a chimeric circle that is recognized by a shift in primer usage and 
is ultimately reflected by the predicted size of IS-PCR product (Figure 2). 
Figure 2. Schematic view of the inverse shifting-PCR approach. The simpler version of  
IS-PCR was described by Rossetti et al. (2005) [15] and involves three steps: (a) genomic 
DNA is subjected to restriction digestion yielding fragments (in this case Bcl I fragments), 
(b) restriction fragments self-end ligation (performed in large volumes), which forms (c) 
DNA  circles  that  represent  templates  for  a  standard  multiplex  PCR  analysis  (on 
background some non relevant circles are shown); (d) PCR products from relevant circles 
are  resolved  by  conventional  electrophoresis.  Lane  1  shows  wild-type  allele-specific 
products (-), lane 2, a male patient hemizygous for Inv22 (+), lane 3, heterozygous Inv22 
carrier female (+/-). On the diagram int22h-1 is shown as a closed chevron; int22h-2 and 
int22h-3  as  grey  and  open  chevrons,  respectively.  Oligonucleotide  primer  ID  indicates 
intragenic downstream, IU, intragenic upstream and ED, extragenic downstream.  
 Int. J. Mol. Sci. 2011, 12  7279 
 
 
Inv22 analysis by IS-PCR was achieved using three different primers (ID, IU, ED) that yielded a 
487 bp amplicon (ID/IU) for the wild-type intragenic allele and a 559 bp amplicon (ED/IU) for the 
Inv22 allele (Figure 2). PCR products were analyzed by standard agarose gel electrophoresis. It is 
important to reinforce that primers for IS-PCR were targeted to regions free of human repeats and  
low-complexity DNA by masking the relevant regions [15].  
2.3. 2005–2011: Completion of the Human X-Chromosome Sequence and Definition of Hypothetical 
int22h-Mediated Rearrangements. Unraveling a Complex Picture 
The traditional picture stated by Naylor et al. (1995), which reigned for a decade, proposed that 
both int22h-2 and int22h-3 should be in opposite orientation to int22h-1 on the X-chromosome [22]. In 
this scenario, intrachromosomal homologous recombination between int22h-1 and either of the two 
extragenic copies may result in the two varieties (types) of the recurrent inversions that cause almost 
half of cases of severe HA. It was believed that int22h-1 interacts with either the proximal (int22h-2), 
or the distal (int22h-3) extragenic copy, generating either Inv22 type II or type I, respectively. By this 
model, interaction between int22h-1 and int22h-3 would be favored over those between int22h-1 and 
int22h-2, thus explaining their relative frequencies (4:1, Inv22 type I: type II) (Naylor et al. 1995) [22].  
Availability of the DNA sequence of the X-chromosome in 2005 showed that int22h-2 and int22h-3 
are found within the arms of a large imperfect palindrome, and only int22h-3 should be involved in 
these inversions [35] (Figure 1A and 1B). The duplicated inverted sections (arms) are 50 kb-long and 
are separated by 67 kb of non-duplicated spacer sequence (Figure 1A and 1B). The int22h-2  and 
int22h-3 regions lie adjacent to the spacer sequence, and the more proximal of these (traditionally 
int22h-2)  is  in  the  same  orientation  as  int22h-1.  Therefore,  recombination  between  int22h-1  and 
int22h-2 should lead to deletions or duplications rather than inversion [36]. 
Bagnall et al. (2005) suggested an attractive hypothesis to explain the relative frequencies of type I 
and  type  II  inversions  [36].  These  investigators  proposed  that  the  large  palindrome  arms  could 
recombine frequently with each other to generate an inversion of the central 67 kb segment (spacer) 
that expresses in the human population as a structural inversion polymorphism with frequencies of 
80% and 20% for the two variants, i.e., h123 and h132, respectively (Figure 1A and 1B). 
2.3.1. More on the Second and Third Generation. New Tests to Allow Comprehensive Detection of 
int22h-Related Rearrangements 
Unfortunately, Inv22 genotyping by LD-PCR (1998) [18] and IS-PCR (2005) [15] does not permit 
discrimination of type I and type II Inv22 patterns (Figure 1C and 1D), nor, perhaps more importantly, 
do these methods allow detection of hypothesized int22h-related deletions (Del22) (Figure 1E and 1F) 
or  duplications  (Dup22)  (Figure  1G).  These  limitations  of  rapid  approaches  for  Inv22  genotyping 
opened up the possibility that molecular diagnosis may be misrepresented in some cases.  
In a bid to overcome these limitations and to improve molecular diagnosis of Inv22, new protocols 
for Inv22 detection based on LD-PCR (2006) [37] and IS-PCR (2008) [16] were developed with the 
intention to identify all int22h rearrangements. Both of these revised protocols allow discrimination of 
Inv22 type I and type II patterns (Figure 1C and 1D), int22h-mediated deletions (Del22-1, Del22-2) Int. J. Mol. Sci. 2011, 12  7280 
 
 
(Figure 1E  and 1F), and duplications (Dup22)  (Figure 1G) by using  complementary or additional 
diagnostics tests (Figure 1A-G(a) and 1A-G(c)).  
Bagnall et al. (2006) [37] developed an LD-PCR based method for specific detection of Inv22 
patterns type I and type II using a single test with four primers (named H1R, H1F, H2F and H3F) 
yielding a 10 kb product in normal DNA representing the intact int22h-1 region, and signals of 11.5 
and 12.7 kb in DNA from patients with the Inv22 type I and type II, respectively [Figure 1C-D(c)]. 
These latter signals represent the more centromeric reciprocal of the int22h recombined sequences, 
which respectively contain part of int22h-3 and int22h-2. DNA samples from  Inv22 heterozygous 
carriers show one of the mentioned Inv22 specific signals accompanied by the 10 kb signal seen in 
normal DNA that contains the non recombined copy of int22h-1 (Figure 1A-B(c)). As equally-oriented 
int22h-mediated duplications and/or deletions were likely to occur, it is useful to have complementary 
tests for detecting and distinguishing them from the inversions that cause severe HA. Consequently, 
Bagnall et al. (2006) [37] designed two complementary tests (Co1° and Co2°) using two combinations 
of primers. The test Co1° with primers H1F and H2/3R shows a signal of 9.6 kb from samples with the 
Inv22-1,  Inv22-2  and  Dup22  [Figure  1C(c),  1D(c)  and  1G(c)],  whereas  Del22  type  I  or  type  II 
associates with an absence of signals; and Co2° with primers H1R, H3F and H2F shows an absence of 
signals from samples with Dup22, and a signal of 11.5 kb from either Inv22 or Del 22 type I alleles 
[Figure 1C(c) and 1E(c)] and 12.7 kb from either Inv22 or Del 22 type II alleles [Figure 1D(c) and 1F(c)].  
Likewise, Rossetti et al. (2008) [16] modified their earlier reported IS-PCR protocol to resolve all 
Bcl I restriction fragments detected by classical Southern blot analysis [11]. This modified protocol 
enables detection of Inv22 type I and type II as well as Del22 type I and type II, and Dup22 [16]. 
Similar to its precursor, this modified IS-PCR protocol avoids direct amplification of int22h duplicons, 
and uses two standard PCR tests for the same substrate (Bcl I circles). The modified protocol includes 
two  multiplex  PCR  assays:  (i)  a  diagnostic  test,  which  is  pattern-sensitive  and  differentiates  HA 
causative Inv22 and Del22 mutations from non-HA causative Dup22 and normal variants; and (ii) a 
complementary test intended to distinguish between Inv22 and Del22, and between Dup22 and normal 
allele. The diagnostic test applies primer ID with a set of three primers U (IU, 2U and 3U), enabling 
discrimination of normal/Dup22 allele, associated with a signal of 487 bp [Figure 1A-B(a) and 1G(a)], 
from Inv22/Del22 type I, with a signal of 333 bp [Figure 1C(a) and 1E(a)], and Inv22/Del22 type II 
with a signal of 385 bp [Figure 1D(a) and 1F(a)]. The complementary test applies primer ED with the 
same set of three primers U, and extends diagnostic test findings [16]. On the complementary test the 
normal allele shows two signals of 457 and 405 bp [Figure 1A-B(a)]; Dup22, three signals of 559, 457 
and 405 bp [Figure 1G(a)]; Inv22 type I, two signals of 457 and 559 bp [Figure 1C(a)]; Del22 type I, 
only one signal of 457 bp [Figure 1E(a)]; Inv22 type II, two signals of 405 and 559 bp [Figure 1D(a)]; 
and Del22 type II shows only one signal of 405 bp [Figure 1F(a)].  
IS-PCR  based  approaches  for  Inv22  genotyping  have  proved  to  enable  detection  and  
semi-quantitative assessment of carrier mosaicisms, and performed robustly over wide ranges of DNA 
qualities and procedural conditions, including for prenatal diagnosis [38]. The key step to achieve 
successful  inverse-PCR  protocols  is  the  formation  of  DNA  circles  from  restriction  fragments  by  
self-end ligation. Rossetti et al. (2008) [16] estimated the circularization efficiency range from 2–10 
units of templates per circle for the formation of DNA circles of approximately 20 kb.  Int. J. Mol. Sci. 2011, 12  7281 
 
 
Despite ongoing efforts to develop technical approaches that would correctly diagnose hypothetical 
equally-oriented int22h-mediated rearrangements [36] (Figure 1), only recently have such genotypes 
been found. Notably, a recent paper of Abou-Elew et al. (2011) [39] reported three cases with signal 
patterns associated with Del22 (two Del22 type II and one Del22 type I) in a group of 13 Egyptian 
patients  with  HA  by  use  of  the  new  IS-PCR  based  two-test  approach.  This  finding  is  somewhat 
unexpected taking into account that Del22 involves a loss of more than 500 kb of genomic DNA 
spanning  a  number  of  genes,  five  of  which  predict  well  characterized  syndromes  with  specifically 
defined  phenotypes  in  addition  to  HA  [40].  In  addition,  Abelleyro  et  al.  (2011)  [40]  presented  a 
different practical approach to support the molecular diagnosis of Del22, by stating the absence or 
presence of a number of evenly spaced STS (sequence tagged sites) in order to confirm or to exclude 
the Del22 associated gap, respectively.  
3. Significance of the Human Genome Project for Inv22 Detection and Diagnosis of HA  
This  review  of  an  important  area  of  molecular  diagnosis  in  humans  clearly  shows  that  the 
development  of  new  genotyping  methods  for  int22h-mediated  rearrangements  relies  on  the 
extraordinary achievements of the Human Genome Project. In particular, the completion and release of 
the human X-chromosome sequence [35] permitted an accurate definition of both hypothetical and 
well established int22h-mediated rearrangements. De Brasi and Bowen (2008) [41] made use of widely 
available  bioinformatic  resources,  such  as  BLAST  (basic  local  alignment  search  tool)  [42]  and  
Smith-Waterman [43] algorithms, to calculate the exact extent of int22h duplicons and their nucleotide 
sequence  differences,  the  size  and  location  of  the  large  inverted  repeats  as  the  arms  of  the  large 
imperfect palindrome int22h-2 and int22h-3, and to precisely define the full range of int22h-mediated 
rearrangements (i.e., Inv22, Del22 and Dup22).  
Moreover, it has been demonstrated that bioinformatic resources developed from Human Genome 
Project initiatives, are providing essential tools for the accurate design of experiments in the molecular 
biology  field.  The  recent  design  of  both  LD-PCR  and  IS-PCR  based  approaches  for  genotyping  
int22h-mediated rearrangements offers two clear examples of this [37,16]. IS-PCR-based genotyping 
for int22h-related rearrangements was designed using the latest version at that time of the nucleotide 
sequence of the human X chromosome, GenBank accession NC_000023.9, nt.153,500,000-154,387,415, 
which encompassed the entire F8, and the centromeric and telomeric arms of the 168 kb imperfect 
palindrome in which int22h-2 and int22h-3 are located.  
Sequence  analysis  required  extensive  application  of  in  silico  tools  including  Bcl  I  restriction 
mapping, DNA sequence alignments, repeat masking, virtual circle formation by self-end ligation and 
oligonucleotide primer selection. Additionally, in order to illustrate the usefulness of bioinformatic 
developments in the area of molecular diagnostic medicine even further, the repeat masker web server 
(URL: http://www.repeatmasker.org) was used to map human repeats throughout all relevant sequences 
in order to limit the primer target sites to human repeat-free regions [15,16].  
In  summary,  three  genotyping  methods  presently  allow  Inv22  analysis  to  discriminate  all  
int22h-mediated rearrangements (i.e., Inv22, Del22 and Dup22), thus reducing potential diagnostic 
mistakes to a minimum. These methods include Southern blot analysis by Lakich et al. (1993) [11], the 
discriminative three-test based LD-PCR by Bagnall et al. (2006) [37], and the discriminative two-test Int. J. Mol. Sci. 2011, 12  7282 
 
 
based IS-PCR by Rossetti et al. (2008) [16]. These three generations of molecular methods for genotyping 
the  hemophilia  inversion  hotspot  are  valuable  examples  of  international  cooperation,  experimental 
ingenuity and, ultimately, scientific evolution to solve challenging molecular diagnostic problems.  
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